{"id":954139,"date":"2026-04-23T08:19:41","date_gmt":"2026-04-23T12:19:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/"},"modified":"2026-04-23T08:19:41","modified_gmt":"2026-04-23T12:19:41","slug":"reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/","title":{"rendered":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CUPERTINO, Calif., April  23, 2026  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva,\u201d the \u201cCompany\u201d \u201cwe\u201d or \u201cus\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET.<\/p>\n<p align=\"justify\">The fireside chat will highlight the recent developments from Reviva\u2019s clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>A.G.P. Fireside Chat<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Format:<\/strong> Fireside Chat<br \/><strong>Date:<\/strong> Monday, April 27, 2026<br \/><strong>Time:<\/strong> 11:00 a.m. ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o8b3ikKGWdUrPJWKLdCRD89tlgb9ncSxV3CU_X89D5iZzB1sEVjw1QwTnulujOQyxMEPWCdLNXQvcL6-kSd6TP4HQqq_d-51ShdDWJRCsHQXbv8bK2eyCWYNFdAxK95HohSUc4ihxjSrdoKhKBa4Lw==\" rel=\"nofollow\" target=\"_blank\">CLICK HERE<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Brilaroxazine<br \/><\/strong>Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in the pathophysiology of several conditions including schizophrenia, psoriasis and interstitial lung diseases like pulmonary hypertension, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Positive topline data from the global Phase 3 RECOVER trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains including reduction in key proinflammatory cytokines implicated in the pathophysiology of schizophrenia and comorbid inflammatory conditions at week 4 with 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates\u00a0<em>lower<\/em>\u00a0than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of the CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with CYP3A4 inhibitors. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit\/hyperactivity disorder (ADHD).<\/p>\n<p align=\"justify\">Additionally, brilaroxazine has shown promising nonclinical activity for inflammatory diseases psoriasis, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of fibrosis and inflammation in translational animal models. Brilaroxazine has already received Orphan Drug Designation by the FDA for the treatment of PAH and IPF conditions. To learn more about the clinical and preclinical data available for brilaroxazine, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4XJTfoMsxwmwPf52WRDuC88ihRwW9L71CMDjd9A-QHR4BEngovp5OtewZUiUILr-qcCDiwaVLjBXyGjXVTa7XftgWvQuHPqXJpJoKj0eAH7KQuN8Dc04VdDLvpqlhgZB4aFPJml0X9CP8px8KrMF_bWfREwIuZ_TRvWgDVbk9fCMbBK7ABeXWG8nvP37067EVdO0UV6sBw5dpSsAzgeaXNlxfRIq9axTO3iMFRYTPeFWnL8rRoS8DU6DTpcjt0eCXmGLV55q8Y72vhYa7QfgB5SRfd7yafrzTtArbldkVQ5iVycBz3B8-_aOP0lFLuOdI9GYiW6ZOsNpj6eASn89Whbj1cSskfTFvSJv6BXC_5i8iC-6HaJKANfLLZCh2kJQtPkyiMIVBzu5KuwvDBkbzELx1NVtX-mmLGIdSbxyg0b7TP9HTTtW2JNaP1wZ8p4Oh7uDXsWBztjb3nsJn8iACIKkaOngXdupUoFjh0WfTt0IcbouPlDuFDzcdweYgN2Q59oEK2evvgpaXej79TwjDwl6DLh-EivEQ0lFSqrGwJgEkcj3b-b7v3MpqXzDBQxHNeXqO6XyJQyazY7mTVApGBAKYysBgj3NefrExitedKJIMIFzjBbyUFpIeX6M38p-b4xjC2qXU479TZMqzXNgKPCnCIwzyT-pQu9p2dMJBBrMZgWhVEtT1OFPEhFoy6K1kw6FPQrNATLZ7DHTMdpmGpG_brqtUQA59lIzKxW9ouFaCn5VyKvrtnwJduDw4I3cvjFPuVT0s2J6zyqFVgB5H8NSV2IvqluDmgw-QhcB1GYimrEIFvlXqAvcaELECUeHzVZgN4sYaR3b1Zy86OsbZ76WMZpVSQXXm9915MGlrEjsy0irCQbrivXnV5BvvA_WplJIgIm7ffwpSFBmx7ZxzgWZ4DZH8AGZ2FUV8muOjD5EKBRdbiUsV1bNvkmIGzR24iDyNFC-4My4XE7aWZhhZ2oNGwDLyz4T1UL7qNRvIQcYTcGtdp3jKXDMKt5bfERzwq52bUO8lRXvSb8QQPv6L6RasYwtGDsAkZmll5Vn_T6jwQwh3eJG6lfuTpY_fypOjcb8n1Y4KB8WQaSy6rPZfAjllM9U2rQPpc8mVrRFX--os3HC2qENJuRFArhmQ9i1stVlmi-y8ioQNiqeo5zX3QtFSdWbC03lWhfsgxnZsNX_9CwhqIpdtMvN3Ge5b9rTlYeKrr6wZdZTF0Xqyh59Qb55rA_P28vePMf4rCjXAQj6KwM6-2nL6rf2I13mQ2tZMDAWYoT8Falrsk-RWXAtINW7GveM95Jz-2GSTOJt28yX21NQSa_rtiQ7hNq0kh2-fV-zybr6x6E17nFrgbqLcg==\" rel=\"nofollow\" target=\"_blank\">revivapharma.com\/publications<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Reviva\u00a0<\/strong><br \/>\n        <br \/>Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=llRcqkDcW7p-cPqu17WhkHq5a1McmyB8sD_B-vX6fmwDPmjqyaWbu17P5Ej7KGaYxXVdOqbjMCD1EWFDkP5UwvyNP-MHsigiFspKRuQDz7c=\" rel=\"nofollow\" target=\"_blank\">www.revivapharma.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>PJ Kelleher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=00kuhI2V_RYZKwlecA7padTzlGAlZSr-NyvyKf-IfY5vZV5NS4rw4Jcv24W4nA4NYg68ykXMvTJu70JCgIUJWvNycMh_qaHGxJQVnfRJzPmg7UqygIRX6zt0MZqUQP3R\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGZiM2I2YjgtZDVkZi00MjFkLTljMGUtYmVhMmZhNDYzYTdhLTUwMDA3NTM4MS0yMDI2LTA0LTIzLWVu\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva,\u201d the \u201cCompany\u201d \u201cwe\u201d or \u201cus\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva\u2019s clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones. A.G.P. Fireside Chat Format: Fireside ChatDate: Monday, April 27, 2026Time: 11:00 a.m. ETWebcast Link: CLICK HERE About BrilaroxazineBrilaroxazine &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva,\u201d the \u201cCompany\u201d \u201cwe\u201d or \u201cus\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva\u2019s clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones. A.G.P. Fireside Chat Format: Fireside ChatDate: Monday, April 27, 2026Time: 11:00 a.m. ETWebcast Link: CLICK HERE About BrilaroxazineBrilaroxazine &hellip; Continue reading &quot;Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T12:19:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications\",\"datePublished\":\"2026-04-23T12:19:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/\"},\"wordCount\":506,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/\",\"name\":\"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\",\"datePublished\":\"2026-04-23T12:19:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/","og_locale":"en_US","og_type":"article","og_title":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk","og_description":"CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva,\u201d the \u201cCompany\u201d \u201cwe\u201d or \u201cus\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva\u2019s clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones. A.G.P. Fireside Chat Format: Fireside ChatDate: Monday, April 27, 2026Time: 11:00 a.m. ETWebcast Link: CLICK HERE About BrilaroxazineBrilaroxazine &hellip; Continue reading \"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-23T12:19:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications","datePublished":"2026-04-23T12:19:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/"},"wordCount":506,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/","name":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==","datePublished":"2026-04-23T12:19:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTYyMSM3NTUxNTA5IzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazines-potential-across-multiple-neuropsychiatric-indications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine\u2019s Potential Across Multiple Neuropsychiatric Indications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}